This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - rimonabant for the treatment of overweight and obese adults

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Summary features of guidance are (1):

  • rimonabant, within its licensed indications, is recommended as an adjunct to diet and exercise for adults who are obese or overweight and who have had an inadequate response to, are intolerant of or are contraindicated to orlistat and sibutramine
  • rimonabant treatment should be continued beyond 6 months only if the person has lost at least 5% of their initial body weight since starting rimonabant treatment
  • rimonabant treatment should be discontinued if a person returns to their original weight while on rimonabant treatment
  • rimonabant treatment should not be continued for longer than 2 years without a formal clinical assessment and discussion of the individual risks and benefits with the person receiving treatment

For full details then consult the full guidance (1).

  • on October 23rd 2008 the European Medicines Agency (EMEA) recommended the suspension of the marketing authorisation for rimonabant (Acomplia). The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of rimonabant no longer outweigh its risks and the marketing authorisation should be suspended across the EU

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.